about
Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors.Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors.Health status and health-related quality of life associated with hemophilia.Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX.
P2860
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Economic aspects of haemophilia care.
@en
Economic aspects of haemophilia care.
@nl
type
label
Economic aspects of haemophilia care.
@en
Economic aspects of haemophilia care.
@nl
prefLabel
Economic aspects of haemophilia care.
@en
Economic aspects of haemophilia care.
@nl
P2093
P2860
P1433
P1476
Economic aspects of haemophilia care.
@en
P2093
Aldedort LM
Goudemand J
P2860
P304
P356
10.1046/J.1365-2516.1999.00325.X
P577
1999-05-01T00:00:00Z